Biotech Values

[DewDiligence]

Do you have any comments on the phase-2b patient pool (stable angina vs unstable angina vs NSTEMI vs STEMI)?

With adequate funding, the best approach would seem to be one phase-2b trial each for unstable angina/NSTEMI and STEMI, especially if the comparator is Angiomax. Such stratification could be important from a mathematical standpoint by enabling the trials to have less statistical noise, and it could be important from a business standpoint because Angiomax usage varies considerably among the sub-indications of ACS.